The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma
Open accessAbstract
Purpose: We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O 6-BG effective in producing complete depletion of tumor AGT activity for 48 hours. The second phase of the trial was designed to define the maximum tolerated dose (MTD) of a single dose of temozolomide when combined with O 6-BG. In addition, plasma concentrations of O 6-BG and O 6-benzyl-8-oxoguanine were evaluated after O 6-BG. Patients and Methods: For our first phase of the clinical trial, patients were scheduled to undergo craniotomy for AGT determination after receiving a 1-hour O 6-BG infusion at 120 mg/m 2 followed by a continuous infusion at an initial dose of 30 mg/m 2/d for 48 hours. The dose of the continuous infusion of O 6-BG escalated until tumor AGT was depleted. Once the O 6-BG dose was established a separate group of patients was enrolled in the second phase of clinical trial, in which temozolomide, administered as a single dose at the end of the 1-hour O 6-BG infusion, was escalated until the MTD was determined. Results: The O 6-BG dose found to be effective in depleting tumor AGT activity at 48 hours was an IV bolus of 120 mg/m 2 over 1 hour followed by a continuous infusion of 30 mg/m 2/d for 48 hours. On enrolling 38 patients in six dose levels of temozolomide, the MTD was established at 472 mg/m 2 with dose-limiting toxicities limited to myelosuppression. Conclusion: This study provides the foundation for a phase II trial of O 6-BG plus temozolomide in temozolomide-resistant MG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Self-citationYung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · cited 1×
“Seven patients with stable disease continued on treatment, having received a median of fivecycles(range,threeto12).Onepatient( 8 )demonstrateda complete response (Fig 1) and remains free of disease after 12 cycles of temozolomide and 33 months off therapy.”
BackgroundSelf-citationStupp, R., Dietrich, P.-Y., Ostermann, S., Pica, A., Maillard, I. P., Maeder, P., Meuli, R. A., Janzer, R. C., Pizzolato, G., Miralbell, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1375 · Cited by 856
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Yung, W. K. A., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R., Olson, J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 761
Self-citationPegg, A. E. (1990) · PubMed · Cited by 730
Self-citationChang, C. H., Horton, J., Schoenfeld, D., Salazer, O., Perez-Tamayo, R., Kramer, S., Weinstein, A., Nelson, J. S., & Tsukada, Y. (1983) · Cancer · doi:10.1002/1097-0142(19830915)52:6<997::aid-cncr2820520612>3.0.co;2-2 · Cited by 598
Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase
Pegg, A. E., Dolan, M. E., & Moschel, R. C. (1995) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(08)60879-x · Cited by 506
Self-citationPhase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
Newlands, E., Blackledge, G., Slack, J., Rustin, G., Smith, D., Stuart, N., Quarterman, C., Hoffman, R., Stevens, M., Brampton, M., et al. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.57 · Cited by 488
Dolan, M. E., Moschel, R. C., & Pegg, A. E. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5368 · Cited by 460
Self-citationFriedman, H. S., McLendon, R. E., Kerby, T., Dugan, M., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3851 · Cited by 423
Self-citationSb, G., Byar, D. P., Walker, Pistenmaa, D. A., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., Mealey, J., Gl, O., et al. (1983) · PubMed · Cited by 404
Stevens, M. F. G., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L. M., Stone, R., BAIG, G. U., Goddard, C. P., Gibson, N. W., & Slack, J. A. (1987) · PubMed · Cited by 387
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372
Jaeckle, K. A., Eyre, H. J., Townsend, J. J., Schulman, S., Knudson, H. M., Belanich, M., Yarosh, D. B., Bearman, S. I., Giroux, D. J., & Schold, S. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3310 · Cited by 297
Belanich, M., Pastor, M., Randall, T., Guerra, D., Kibitel, J. T., Alas, L., Li, B., Citron, M. L., Wasserman, P., White, A., et al. (1996) · PubMed · Cited by 244
Repair of DNA containing O 6 ‐alkylguanine
Pegg, A. E., & Byers, T. L. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.6.1544541 · Cited by 242
Self-citationMulticentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
Bower, M., Newlands, E. S., Bleehen, N. M., Brada, M., Begent, R. J. H., Calvert, H., Colquhoun, I., Lewis, P., & Brampton, M. H. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050691 · Cited by 221
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.
Friedman, H. S., Kokkinakis, D. M., Pluda, J., Friedman, A. H., Cokgor, I., Haglund, M. M., Ashley, D. M., Rich, J., Dolan, M. E., Pegg, A. E., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3570 · Cited by 213
Self-citationO6-benzylguanine and its role in chemotherapy.
Dolan, M. E., & Pegg, A. E. (1997) · PubMed · Cited by 211
Self-citationLudlum, D. B. (1990) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/0027-5107(90)90156-x · Cited by 209
Quinn, J. A., Pluda, J., Dolan, M. E., Delaney, S., Kaplan, R., Rich, J. N., Friedman, A. H., Reardon, D. A., Sampson, J. H., Colvin, O. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.084 · Cited by 189
Self-citationRegulation of Repair of Alkylation Damage in Mammalian Genomes
Mitra, S., & Kaina, B. (1993) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(08)60218-4 · Cited by 164
Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine
Pegg, A. E., Boosalis, M. S., Samson, L. D., Moschel, R. C., Byers, T. L., Swenn, K., & Dolan, M. E. (1993) · Biochemistry · doi:10.1021/bi00096a009 · Cited by 151
Self-citationTherapy of adult malignant brain tumors: what have the clinical trials taught us?
Shapiro, W. R. (1986) · PubMed · Cited by 145
Pulmonary Toxicity Associated with Bischloroethylnitrosourea (BCNU)
Durant, J. R., NORGARD, M. J., MURAD, T. M., BARTOLUCCI, A. A., & LANGFORD, K. H. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-90-2-191 · Cited by 143
The basis for current treatment recommendations for malignant gliomas
Fine, H. A. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01052722 · Cited by 129
Spiro, T. P., Gerson, S. L., Liu, L., Majka, S. M., Haaga, J. R., Hoppel, C. L., Ingalls, S. T., Pluda, J. M., & Willson, J. K. V. (1999) · PubMed · Cited by 126
Wedge, S. R., Porteous, J. K., & Newlands, E. S. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.485 · Cited by 123
Friedman, H. S., Pluda, J. M., Quinn, J. A., Ewesuedo, R. B., Long, L., Friedman, A. H., Cokgor, I., Colvin, O. M., Haglund, M. M., Ashley, D. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3522 · Cited by 116
Self-citationGriffin, S., Branch, P., Xu, Y., et al. (1994) · Biochemistry · doi:10.1021/bi00182a006 · Cited by 109
Mitchell, R. B., Moschel, R. C., & Dolan, M. E. (1992) · PubMed · Cited by 103
Self-citationClinically significant pharmacokinetic drug interactions between antiepileptic drugs
Tanaka, E. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00201.x · Cited by 96
Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine: a comparative study in vitro
Wedge, S. R., Porteous, J. K., May, B., & Newlands, E. S. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.85 · Cited by 95
Dolan, M. E., Stine, L., Mitchell, R. B., Moschel, R. C., & Pegg, A. E. (1990) · Cancer Communications · doi:10.3727/095535490820873985 · Cited by 94
Self-citationTemozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study
Brandes, A. A., Ermani, M., Basso, U., Amistà, P., Berti, F., Scienza, R., Rotilio, A., Pinna, G. D., Gardiman, M. P., & Monfardini, S. (2001) · Annals of Oncology · doi:10.1023/a:1008336732273 · Cited by 91
TRANSCRIPTIONAL ACTIVATION OF CYTOCHROME P450 GENES BY DIFFERENT CLASSES OF CHEMICAL INDUCERS
Dogra, S. C., Whitelaw, M. L., & May, B. K. (1998) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1998.tb02135.x · Cited by 86
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Khan, R. B. (2002) · Neuro-Oncology · doi:10.1215/15228517-4-1-39 · Cited by 85
Wedge, S. R., & Newlands, E. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.203 · Cited by 84
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
Dolan, M. E., Roy, S. K., Fasanmade, A. A., Paras, P. R., Schilsky, R. L., & Ratain, M. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1803 · Cited by 82
Self-citationHOTTA, T., Saito, Y., Fujita, H., Mikami, T., Kurisu, K., Kiya, K., Uozumi, T., Isowa, G., Ishizaki, K., & Ikenaga, M. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01052897 · Cited by 70
Prados, M. D., Yung, W. K. A., Fine, H. A., Greenberg, H. S., Junck, L., Chang, S. M., Nicholas, M. K., Robins, H. I., Mehta, M. P., Fink, K., et al. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000309 · Cited by 68
Dolan, M. E., Morimoto, K. Y., & Pegg, A. E. (1985) · PubMed · Cited by 67
Self-citationO6-methylguanine residues elicit DNA repair synthesis by human cell extracts
Karran, P., Macpherson, P. C. D., Ceccotti, S., Dogliotti, E., Griffin, S., & Bignami, M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82335-3 · Cited by 67
Gibson, N. W., Hickman, J. A., & Erickson, L. C. (1984) · PubMed · Cited by 66
Wedge, S. R., Porteous, J. K., & Newlands, E. S. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050657 · Cited by 57
Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase.
Dolan, M. E., Chae, M.-Y., Pegg, A. E., Mullen, J. H., Friedman, H. S., & Moschel, R. C. (1994) · PubMed · Cited by 53
Self-citationChang, S. M., Prados, M. D., Yung, W. K. A., Fine, H. A., Junck, L., Greenberg, H. S., Robins, H. I., Mehta, M. P., Fink, K., Jaeckle, K. A., et al. (2004) · Cancer · doi:10.1002/cncr.20157 · Cited by 52
Reese, J., Davis, B. M., Liu, L., & Gerson, S. L. (1999) · PubMed · Cited by 46
Hirose, Y., Kreklau, E. L., Erickson, L. C., Berger, M. S., & Pieper, R. O. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.98.3.0591 · Cited by 39
Janinis, J., Efstathiou, E., Panopoulos, C. G., Samantas, E., Aravantinos, G., Christodoulou, C., & Skarlos, D. V. (2000) · Medical Oncology · doi:10.1007/bf02796204 · Cited by 19
Preclinical approach for identifying drug interactions
Kamataki, T., Yokoi, T., Fujita, K., & Ando, Y. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051079 · Cited by 14
Cited by
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812
Metadata
- Authors
- Quinn, J. A., Desjardins, A., Weingart, J., Brem, H., Dolan, M. E., Delaney, S. M., Vredenburgh, J., Rich, J., Friedman, A. H., Reardon, D. A., Sampson, J. H., Pegg, A. E., Moschel, R. C., Birch, R., McLendon, R. E., Provenzale, J. M., Gururangan, S., Dancey, J. E., Maxwell, J., Tourt-Uhlig, S., Herndon, J. E., Bigner, D. D., & Friedman, H. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-10-01
- Volume
- 23
- Issue
- 28
- Pages
- 7178-7187
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2138545604
- Cited by
- 288
- References
- 55
- FWCI
- 12.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.